PRPOPrecipio, Inc.
30.45USD+9.34%Mkt Cap: 54.51M $P/E: —3d ago
Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a…
Industry Peers
Diagnostics & Research$232.67BUSDP/E 33.9
$153.85BUSDP/E 39.0
$47.21BUSDP/E 38.3
$47.86BUSD
$44.91BUSDP/E 31.9
$43.93BUSDP/E 39.1
$42.77BUSDP/E 32.3
$40.32BUSDP/E 103.5
$33.13BUSDP/E 41.0
$27.96BUSDP/E 31.5
$27.28BUSDP/E 27.8
$26.97BUSDP/E 26.0
$22.91BUSD
$17.33BUSDP/E 36.4
$13.65BUSDP/E 25.3
$14.09BUSD
$13.92BUSDP/E 59.7
$13.29BUSDP/E 269.1
$9.55BUSDP/E 19.1
$9.13BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
Precipio Inc (PRPO) (Q2 2026) Earnings Call Highlights: Record Revenue and Positive EBITDA Mark ... Precipio Inc (PRPO) surpasses $7 million in quarterly revenue, achieves positive adjusted EBITDA, and generates strong operating cash flow. | ||
 Precipio, Inc. Q2 2026 Earnings Call Summary Moby summary of Precipio, Inc.'s Q2 2026 earnings call | ||
 PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy? Precipio and NeoGenomics take different approaches to cancer diagnostics, but which oncology stock looks more compelling now? Let's dive in. | ||